Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452
Vaccine, October 29, 2021
Shelf-stable for over six months at 25° Celsius (77° Fahrenheit)
Maintains potency for one month at 37° Celsius (99° Fahrenheit)
Uses established antibody production infrastructure
Single production line can make over one billion doses per year
Designed to preserve effectiveness against viral variants
Vaccine, October 29, 2021
Papers
In the News
Akston Press
Akston Biosciences Corporation leverages its novel fusion protein platform to develop and manufacture new classes of biologics, including vaccines, ultra-long-acting insulins, and autoimmune disease therapies. Founded by the team that developed the world’s first clinical glucose-responsive insulin at SmartCells, Inc. (sold to Merck & Co.), Akston has partnered with Dechra Pharmaceuticals PLC (DPH) to commercialize once-a-week canine and feline insulin therapies. It operates a GMP biologics manufacturing facility and research laboratory at its Beverly, Massachusetts location.